Main Article Content

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive disorder linked to mutations in the ATM gene, and is characterized by neurodegeneration with an early onset cerebellar syndrome, hyperkinetic movement disorders, neuropathy, and oculocutaneous telangiectasia. Immunodeficiency, pulmonary disease, growth failure, diabetes mellitus, increased malignancy risk and hypersensitivity to ionizing radiation complicate the clinical picture. Serum alpha-fetoprotein levels are increased in patients with A-T and can therefore serve as a diagnostic marker for the disease. In resource-limited settings, diagnosis and management of patients with a rare and complex disorder such as A-T may be extremely challenging. This expert opinion-based guideline aims to give an overview of diagnosis and management of A-T in resource-limited settings, by prioritizing different options based on medical necessity, availability, and costs.

Article Details

How to Cite
van Os, N. J., van Aerde, K. J., van Gaalen, J., Merkus, P. J., Silveira-Moriyama, L., Tajudin, T. A., van de Warrenburg, B. P., Weemaes, C. M., Dekker, M. C., & Willemsen, M. A. (2020). Diagnosis and Management of Ataxia-Telangiectasia in Resource-Limited Settings. Journal of the International Child Neurology Association, 1(1). https://doi.org/10.17724/jicna.2020.181

References

  1. 1. Swift, M., D. Morrell, E. Cromartie, A.R. Chamberlin, M.H. Skolnick, and D.T. Bishop, The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet, 1986. 39(5): p. 573-83.
  2. 2. Savitsky, K., A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D.A. Tagle, S. Smith, T. Uziel, S. Sfez, et al., A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 1995. 268(5218): p. 1749-53.
  3. 3. Sedgwick, R.P. and E. Boder, Ataxia-Telangiectasia in Handbook of Clinical Neurology, P.J. Vinken, G.W. Bruyn, and H. Klawans, Editors. 1991, Elsevier: New York, USA. p. 347-393.
  4. 4. van Os, N.J.H., A.F.M. Jansen, M. van Deuren, A. Haraldsson, N.T.M. van Driel, A. Etzioni, M. van der Flier, C.A. Haaxma, T. Morio, A. Rawat, et al., Ataxia-telangiectasia: Immunodeficiency and survival. Clin Immunol, 2017. 178: p. 45-55.
  5. 5. van Os, N.J.H., A. Hensiek, J. van Gaalen, A.M.R. Taylor, M. van Deuren, C.M.R. Weemaes, M. Willemsen, and B.P.C. van de Warrenburg, Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia. Neurology, 2019. 92(1): p. e19-e29.
  6. 6. Verhagen, M.M., W.F. Abdo, M.A. Willemsen, F.B. Hogervorst, D.F. Smeets, J.A. Hiel, E.R. Brunt, M.A. van Rijn, D. Majoor Krakauer, R.A. Oldenburg, et al., Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology, 2009. 73(6): p. 430-7.
  7. 7. Landoure, G., F. Mochel, K. Meilleur, M. Ly, M. Sangare, N. Bocoum, K. Bagayoko, T. Coulibaly, A.M. Sarr, H.O. Ba, et al., Novel mutation in the ATM gene in a Malian family with ataxia telangiectasia. J Neurol, 2013. 260(1): p. 324-6.
  8. 8. Wagstaff, L.A. and R. Joffe, Ataxia-telangiectasia in a South African Bantu child. S Afr Med J, 1969. 43(21): p. 662-4.
  9. 9. van Os, N.J., C.A. Haaxma, M. van der Flier, P.J. Merkus, M. van Deuren, I.J. de Groot, J. Loeffen, B.P. van de Warrenburg, and M.A. Willemsen, Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol, 2017.
  10. 10. Dekker, M.C.J., S.J. Urasa, and W.P. Howlett, Neurological letter from Kilimanjaro. Practical Neurology, 2017. 0: p. 1-5.
  11. 11. McLane, H.C., A.L. Berkowitz, B.N. Patenaude, E.D. McKenzie, E. Wolper, S. Wahlster, G. Fink, and F.J. Mateen, Availability, accessibility, and affordability of neurodiagnostic tests in 37 countries. Neurology, 2015. 85(18): p. 1614-22.
  12. 12. Bower, J.H. and G. Zenebe, Neurologic services in the nations of Africa. Neurology, 2005. 64(3): p. 412-5.
  13. 13. Schoenaker, M.H., F. Suarez, T. Szczepanski, N. Mahlaoui, and J.L. Loeffen, Treatment of acute leukemia in children with ataxia telangiectasia (A-T). Eur J Med Genet, 2016.
  14. 14. Bhatt, J.M., A. Bush, M. van Gerven, A. Nissenkorn, M. Renke, L. Yarlett, M. Taylor, T. Tonia, A. Warris, S. Zielen, et al., ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev, 2015. 24(138): p. 565-81.
  15. 15. Yip, C.H., D.G. Evans, G. Agarwal, I. Buccimazza, A. Kwong, R. Morant, I. Prakash, C.Y. Song, N.A. Taib, C. Tausch, et al., Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. World J Surg, 2019. 43(5): p. 1264-1270.
  16. 16. van Os, N.J., N. Roeleveld, C.M. Weemaes, M.C. Jongmans, G.O. Janssens, A.M. Taylor, N. Hoogerbrugge, and M.A. Willemsen, Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet, 2016. 90(2): p. 105-17.
  17. 17. Waldmann, T.A. and K.R. McIntire, Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. Lancet, 1972. 2(7787): p. 1112-5.
  18. 18. Schieving, J.H., M. de Vries, J.M. van Vugt, C. Weemaes, M. van Deuren, J. Nicolai, R.A. Wevers, and M.A. Willemsen, Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur J Paediatr Neurol, 2014. 18(3): p. 243-8.
  19. 19. Stray-Pedersen, A., A.L. Borresen-Dale, E. Paus, C.R. Lindman, T. Burgers, and T.G. Abrahamsen, Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol, 2007. 11(6): p. 375-80.
  20. 20. Weiss, B., A. Krauthammer, M. Soudack, A. Lahad, I. Sarouk, R. Somech, G. Heimer, B. Ben-Zeev, and A. Nissenkorn, Liver Disease in Pediatric Patients With Ataxia Telangiectasia: A Novel Report. J Pediatr Gastroenterol Nutr, 2016. 62(4): p. 550-5.
  21. 21. Paulino, T.L., M.N. Rafael, S. Hix, D.C. Shigueoka, S.A. Ajzen, C. Kochi, F.I. Suano-Souza, R. da Silva, B.T. Costa-Carvalho, and R.O.S. Sarni, Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? Orphanet J Rare Dis, 2017. 12(1): p. 136.
  22. 22. Klockgether, T., C. Mariotti, and H.L. Paulson, Spinocerebellar ataxia. Nat Rev Dis Primers, 2019. 5(1): p. 24.
  23. 23. Cook, A. and P. Giunti, Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull, 2017. 124(1): p. 19-30.
  24. 24. Schuelke, M., Ataxia with Vitamin E Deficiency, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993, University of Washington, Seattle: Seattle (WA).
  25. 25. Shimazaki, H., Y. Takiyama, K. Sakoe, K. Ikeguchi, K. Niijima, J. Kaneko, M. Namekawa, T. Ogawa, H. Date, S. Tsuji, et al., Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations. Neurology, 2002. 59(4): p. 590-5.
  26. 26. Moreira, M.C. and M. Koenig, Ataxia with Oculomotor Apraxia Type 2, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993, University of Washington, Seattle: Seattle (WA).
  27. 27. Al Tassan, N., D. Khalil, J. Shinwari, L. Al Sharif, P. Bavi, Z. Abduljaleel, N. Abu Dhaim, A. Magrashi, S. Bobis, H. Ahmed, et al., A missense mutation in PIK3R5 gene in a family with ataxia and oculomotor apraxia. Hum Mutat, 2012. 33(2): p. 351-4.
  28. 28. Bras, J., I. Alonso, C. Barbot, M.M. Costa, L. Darwent, T. Orme, J. Sequeiros, J. Hardy, P. Coutinho, and R. Guerreiro, Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4. Am J Hum Genet, 2015. 96(3): p. 474-9.
  29. 29. Sun, Y.M., C. Lu, and Z.Y. Wu, Spinocerebellar ataxia: relationship between phenotype and genotype - a review. Clin Genet, 2016. 90(4): p. 305-14.
  30. 30. Tsagalioti, E., C. Trifonos, A. Morari, K. Vadikolias, and C. Giaginis, Clinical value of nutritional status in neurodegenerative diseases: What is its impact and how it affects disease progression and management? Nutr Neurosci, 2018. 21(3): p. 162-175.
  31. 31. Black, R.E., L.H. Allen, Z.A. Bhutta, L.E. Caulfield, M. de Onis, M. Ezzati, C. Mathers, and J. Rivera, Maternal and child undernutrition: global and regional exposures and health consequences. Lancet, 2008. 371(9608): p. 243-60.
  32. 32. Ross, L.J., S. Capra, B. Baguley, K. Sinclair, K. Munro, P. Lewindon, and M. Lavin, Nutritional status of patients with ataxia-telangiectasia: A case for early and ongoing nutrition support and intervention. J Paediatr Child Health, 2015. 51(8): p. 802-7.
  33. 33. Ehlayel, M., A. Soliman, and V. De Sanctis, Linear growth and endocrine function in children with ataxia telangiectasia. Indian J Endocrinol Metab, 2014. 18(Suppl 1): p. S93-6.
  34. 34. Lefton-Greif, M.A., T.O. Crawford, J.A. Winkelstein, G.M. Loughlin, C.B. Koerner, M. Zahurak, and H.M. Lederman, Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr, 2000. 136(2): p. 225-31.
  35. 35. Nissenkorn, A., Y. Levy-Shraga, Y. Banet-Levi, A. Lahad, I. Sarouk, and D. Modan-Moses, Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res, 2016.
  36. 36. Johnson, A., C. Gambrah-Sampaney, E. Khurana, J. Baier, E. Baranov, B. Monokwane, and D.R. Bearden, Risk Factors for Malnutrition Among Children With Cerebral Palsy in Botswana. Pediatr Neurol, 2017. 70: p. 50-55.
  37. 37. Jahan, I., M. Muhit, T. Karim, H. Smithers-Sheedy, I. Novak, C. Jones, N. Badawi, and G. Khandaker, What makes children with cerebral palsy vulnerable to malnutrition? Findings from the Bangladesh cerebral palsy register (BCPR). Disabil Rehabil, 2019. 41(19): p. 2247-2254.
  38. 38. Garcia-Contreras, A.A., E.M. Vasquez-Garibay, E. Romero-Velarde, A.I. Ibarra-Gutierrez, R. Troyo-Sanroman, and I.E. Sandoval-Montes, Intensive nutritional support improves the nutritional status and body composition in severely malnourished children with cerebral palsy. Nutr Hosp, 2014. 29(4): p. 838-43.
  39. 39. Polack, S., M. Adams, D. O'Banion, M. Baltussen, S. Asante, M. Kerac, M. Gladstone, and M. Zuurmond, Children with cerebral palsy in Ghana: malnutrition, feeding challenges, and caregiver quality of life. Dev Med Child Neurol, 2018. 60(9): p. 914-921.
  40. 40. Zuurmond, M., D. O'Banion, M. Gladstone, S. Carsamar, M. Kerac, M. Baltussen, C.J. Tann, G. Gyamah Nyante, and S. Polack, Evaluating the impact of a community-based parent training programme for children with cerebral palsy in Ghana. PLoS One, 2018. 13(9): p. e0202096.
  41. 41. Chow, C.K., C. Ramasundarahettige, W. Hu, K.F. AlHabib, A. Avezum, Jr., X. Cheng, J. Chifamba, G. Dagenais, A. Dans, B.A. Egbujie, et al., Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol, 2018. 6(10): p. 798-808.
  42. 42. Rothblum-Oviatt, C., J. Wright, M.A. Lefton-Greif, S.A. McGrath-Morrow, T.O. Crawford, and H.M. Lederman, Ataxia telangiectasia: a review. Orphanet J Rare Dis, 2016. 11(1): p. 159.
  43. 43. Charlesworth, G., M.D. Mohire, S.A. Schneider, M. Stamelou, N.W. Wood, and K.P. Bhatia, Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology, 2013. 81(13): p. 1148-51.
  44. 44. Davies, E.G., Update on the management of the immunodeficiency in ataxia-telangiectasia. Expert Rev Clin Immunol, 2009. 5(5): p. 565-75.
  45. 45. World Health Organization recommendations for routine immunization - summary tables. 26 April 2019; Available from: https://www.who.int/immunization/policy/immunization_tables/en/.
  46. 46. Bodemer, C., V. Sauvage, N. Mahlaoui, J. Cheval, T. Couderc, S. Leclerc-Mercier, M. Debre, I. Pellier, L. Gagnieur, S. Fraitag, et al., Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect, 2014. 20(10): p. O656-63.
  47. 47. Buchbinder, D., F. Hauck, M.H. Albert, A. Rack, S. Bakhtiar, A. Shcherbina, E. Deripapa, K.E. Sullivan, L. Perelygina, M. Eloit, et al., Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. J Clin Immunol, 2019. 39(1): p. 81-89.
  48. 48. Chiam, L.Y., M.M. Verhagen, A. Haraldsson, N. Wulffraat, G.J. Driessen, M.G. Netea, C.M. Weemaes, M.M. Seyger, and M. van Deuren, Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? Dermatology, 2011. 223(1): p. 13-9.
  49. 49. Woelke, S., E. Valesky, S. Bakhtiar, H. Pommerening, L.M. Pfeffermann, R. Schubert, and S. Zielen, Treatment of Granulomas in Patients With Ataxia Telangiectasia. Front Immunol, 2018. 9: p. 2000.
  50. 50. Sarmiento, J.D., F. Villada, J.C. Orrego, J.L. Franco, and C.M. Trujillo-Vargas, Adverse events following immunization in patients with primary immunodeficiencies. Vaccine, 2016. 34(13): p. 1611-1616.
  51. 51. Heiman, S., M. Weil, L.M. Shulman, A.J. Simon, A. Lev, R. Somech, and T. Stauber, Co-appearance of OPV and BCG vaccine-derived complications in two infants with severe combined immunodeficiency. Immunol Res, 2018. 66(3): p. 437-443.
  52. 52. Schroeder, S.A. and S. Zielen, Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol, 2014. 49(4): p. 389-99.
  53. 53. Bhatt, J.M. and A. Bush, Microbiological surveillance in lung disease in ataxia telangiectasia. Eur Respir J, 2014. 43(6): p. 1797-801.
  54. 54. Kibirige, D., L. Kampiire, D. Atuhe, R. Mwebaze, W. Katagira, W. Muttamba, R. Nantanda, W. Worodria, and B. Kirenga, Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective. BMC Pulm Med, 2017. 17(1): p. 179.
  55. 55. Molyneux, E., T. Scanlan, G. Chagaluka, and L. Renner, Haematological cancers in African children: progress and challenges. Br J Haematol, 2017. 177(6): p. 971-978.
  56. 56. Israels, T., L. Renner, M. Hendricks, P. Hesseling, S. Howard, and E. Molyneux, SIOP PODC: recommendations for supportive care of children with cancer in a low-income setting. Pediatr Blood Cancer, 2013. 60(6): p. 899-904.
  57. 57. Verhagen, M.M., M. van Deuren, M.A. Willemsen, H.J. Van der Hoeven, Y.F. Heijdra, J.B. Yntema, C.M. Weemaes, and C. Neeleman, Ataxia-Telangiectasia and mechanical ventilation: a word of caution. Pediatr Pulmonol, 2009. 44(1): p. 101-2.
  58. 58. Lockman, J.L., A.J. Iskander, M. Bembea, T.O. Crawford, H.M. Lederman, S. McGrath-Morrow, and R.B. Easley, Anesthetic and perioperative risk in the patient with Ataxia-Telangiectasia. Paediatr Anaesth, 2012. 22(3): p. 256-62.
  59. 59. Ataxia Telangiectasia Children's Project website - A-T child and oligo selected for aso gene therapy. 26 July 2019]; Available from: https://www.atcp.org/a-t-child-and-oligo-selected-for-aso-gene-therapy/.
  60. 60. Ataxia Telangiectasia Treatment with the EryDex System. 26 June 2019]; Available from: http://attest-trial.com/.
  61. 61. ClinicalTrials.gov - Effects of Vitamin B3 in Patients with Ataxia Telangiectasia 26 June 2019]; Available from: https://clinicaltrials.gov/ct2/show/NCT03962114?cond=Ataxia-telangiectasia&rank=10.
  62. 62. Zhong, A., B. Darren, B. Loiseau, L.Q.B. He, T. Chang, J. Hill, and H. Dimaras, Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review. Genet Med, 2018.
  63. 63. Groot, M.T., R. Baltussen, C.A. Uyl-de Groot, B.O. Anderson, and G.N. Hortobagyi, Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J, 2006. 12 Suppl 1: p. S81-90.
  64. 64. Gyawali, B., T. Shimokata, K. Honda, H. Tsukuura, and Y. Ando, Should low-income countries invest in breast cancer screening? Cancer Causes Control, 2016. 27(11): p. 1341-1345.